Slides

Managing TTR Amyloidosis Module 1 slides

Resources

• Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines 2019;7:11
• Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47:625-38.
• Coelho T, Ericzon B-G, Falk R, et al. Amyloidosis Foundation Physician’s Guide. 2016. Available at http://www.amyloidosis.org/wp-content/uploads/2017/05/2017-ATTR-guide.pdf
• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
• Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107-S112.
• Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013 Jan;29(1):63-76.
• Conceição I, González-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21:5-9.
• Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007; 69:693-698.
• Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879-2887.
• Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826-1834.
• Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7:709-716.
• Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood. 2012;120:3206-3213.
• Castaño A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23:1355-1363.
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133:2404-2412.
• Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5:755-758.

Provided by

Support for the activities in this curriculum has been made possible through an educational grant from Akcea Therapeutics.

Course Description

By learning more about the pathophysiology of rare diseases like TTR Amyloidosis, members of the care team who may encounter these patients on their diagnostic journeys can have a profound impact on their ultimate outcomes.

Learning Objective

After participating in the activity, learners should be better able to:

• Describe the epidemiology and pathophysiology of TTR amyloidosis

Release date: 11/30/19
Expiration date: 11/30/20
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours

Activity Faculty

Morie A Gertz, MD, MACP
Consultant - Division of Hematology, Department of Internal Medicine
Mayo Clinic
Professor of Medicine
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Target Audience

The target audience for this initiative is physicians and other providers, including nurse practitioners and physician assistants, who may encounter patients in their practice with undiagnosed TTR amyloidosis.

Accreditation and Credit Designation

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the brief post assessment and evaluation. Your certificate can be available immediately.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Faculty Educator

Dr. Gertz discloses the following relationships with commercial interests:
Advisory Boards: Ionis/Akcea, Alnylam, Prothena, Spectrum Annexon, Appellis, Amgen
Data Safety Monitoring Board: AbbVie
Speaker Fees: DAVA Oncology; Pharmacyclics Proclara

Planning Committee

Activity planners have no relevant financial relationships with any commercial interests to disclose.

Disclaimer

This activity may contain discussion of off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: [email protected]

Copyright

© 2019. This CME-certified activity is held as copyrighted © by CheckRare CE Inc and American Academy of CME, Inc. Through this notice, the owners grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.